Hepatitis C
AASLD 2011: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
A dual antiviral regimen containing the novel hepatitis C virus (HCV) NS5A inhibitor daclatasvir (BMS-790052) plus the NS3 protease inhibitor asunaprevir (BMS-650032) -- without interferon -- produced rapid and sustained viral suppression in Japanese prior null responders with HCV genotype 1b, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
AASLD 2011: PSI-7977 plus Ribavirin Can Cure Hepatitis C in 12 Weeks without Interferon
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
An all-oral dual regimen containing Pharmasset's hepatitis C virus (HCV) polymerase inhibitor PSI-7977 plus ribavirin produced 100% sustained response at 12 weeks in previously untreated people with HCV genotypes 2 or 3, according to findings from the ELECTRON study reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
Hepatitis C Patients May Have Increased Risk of Stroke
- Details
- Category: Cardiovascular Disease
- Published on Friday, 28 October 2011 00:00
People with chronic hepatitis C virus (HCV) infection appear to have a higher likelihood of dying from strokes than uninfected individuals, according to research reported in the December 2010 issue of Stroke. Over 17 years of follow-up, nearly 3% of HCV seropositive people dieddue to cerebrovascular events, compared with 1% of HCV negative people; furthermore, the risk of stroke death rose with increasing HCV viral load.
Pharmasset Starts Phase 3 Trials of PSI-7977 Without Interferon
- Details
- Category: HCV Treatment
- Published on Friday, 04 November 2011 00:00
Pharmasset, Inc. announced this week that it has begun a Phase 3 program of studies of its hepatitis C virus (HCV) polymerase inhibitor PSI-7977 taken once-daily in combination with ribavirin but not pegylated interferon. These trials will enroll previously untreated people with HCV genotype 2 or 3, and patients with any genotype who cannot use interferon.
Vertex to Test 12-Week Telaprevir for People with Favorable IL28B Gene Pattern
- Details
- Category: HCV Treatment
- Published on Friday, 28 October 2011 00:00
Vertex Pharmaceuticals this week announced the initiation of a new Phase 3b clinical trial (CONCISE) to test whether the recently approved hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) plus pegylated interferon/ribavirin can cure treatment-naive patients and prior relapsers with the favorable IL28B CC gene pattern in just 12 weeks.
High Rate of HCV Infection Shows Young Drug Injectors Need Better Prevention Interventions
- Details
- Category: HCV Epidemiology & Mortality
- Published on Tuesday, 01 November 2011 00:00
Young infection drug users (IDUs) continue to become infected with hepatitis C at an alarming rate, underscoring the need for new and better prevention efforts, according to a study described in the October 28, 2011, issue of the CDC's Morbidity and Mortality Weekly Report.
HCV Polymerase Inhibitor Setrobuvir Looks Safe and Effective in Interim Analysis
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
The investigational hepatitis C virus (HCV) polymerase inhibitor setrobuvir (ANA598) has demonstrated good efficacy to date in an ongoing Phase 2b trial, producing viral suppression in more than three-quarters of prior non-responders and relapsers. About 70% of treatment-naive patients were eligible for short-duration treatment based on early virological response.
Achillion Finds Promising New HCV NS5A Inhibitor Candidate
- Details
- Category: HCV Treatment
- Published on Tuesday, 01 November 2011 00:00
Achillion Pharmaceuticals recently announced that it has selected a second-generation hepatitis C virus (HCV) NS5A inhibitor for development, designated ACH-3102. NS5A inhibitors are among the direct-acting antiviral agents that have begun to revolutionize hepatitis C treatment. The function of the HCV NS5A protein is not fully understood, but it appears to both play a role in viral replication and influence host response.
EACS 2011: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
Hepatitis C virus (HCV) RNA levels rise over time in HIV/HCV coinfected people, reducing the chances of sustained response to interferon-based treatment. But antiretroviral therapy may help control HCV viral load and contribute to higher likelihood of treatment success, according to a report presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.
More Articles...
- IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People
- AASLD Hepatitis C Treatment Guidelines Updated to Include Boceprevir and Telaprevir
- EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People
- EACS 2011: People on Methadone Maintenance Can Be Successfully Treated for Hepatitis C
- FDA Approves Pegasys Autoinjector for Hepatitis C Patients
Web Design and Development by